Clinical trial
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With…
NCT00126893 · Celgene Corporation, Industry · Terminated
Key facts
| NCT number | NCT00126893 |
|---|---|
| Title | Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia |
| Official title | Phase 1 Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | CC-401 |
| Enrollment | 36 |
| Start date | Oct 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Aug 5, 2005 |
| Last update posted | May 15, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: